DePaul University Research Services > Research Protections > Institutional Biosafety Committee (IBC)

Institutional Biosafety Committee (IBC)

News & Announcements

Post date 10-11-2022 Announcement:

The Director of Research Compliance will be on maternity leave from October 12th, 2022 until January 4th, 2023.  Please forward all IBC inquiries to the emailbox or to Janine Kirin at You may also contact the IBC Chair, Justin Maresh, at

Post date 7-22-2020 Announcement:

The server housing eProtocol will be down for routine maintenance Sunday, July 26, 2020 from 6 AM to 6 PM.

Post date 7-20-20 Announcement:

CITI has created a special COVID back to campus module, which is available for free until September 30, 2020. There are three basic modules and three optional modules. We are providing the optional training for DePaul faculty, staff and students as a resource. Follow these instructions to access the training: COVID19 - Subscriber instructions for posting.pdf

Announcement: The IBC module for the online submission eProtocol platform was implemented on January 2, 2020. (posted 1/28/2020)

The online paperless eProtocol system was implemented for the IBC effective January 2, 2020. This means that all new IBC protocols should be submitted through that system. Please go the tab called IBC Protocol Portal on the left navigation bar for more information about the online submission process. All currently approved protocols are being transitioned to the electronic system as soon as possible.

Announcement: The IBC announces the release of new Guidance and Education for Receipt of and Transport of Biohazardous Materials (posted 12/18/2019)

In response to feedback from faculty, the IBC re-evaluated their policy for requiring CITI shipping training when the activity is limited to transport only. The IBC created the new guidance document, which will be used internally to document that personnel listed on an IBC protocol who will transport or receive biohazardous materials have read the training/education material. We will no longer require CITI shipping training for protocols limited to transport of materials. CITI shipping training will still be required for personnel who will ship biohazardous materials.

Announcement: The IBC announces the release of the new IBC Policy and Procedure Manual and completely revised forms (posted: 9/16/2016)

The IBC has released the new IBC Policy and Procedure Manual. The new manual is posted on the Policies and Procedure section of the IBC page. The manual supercedes the IBC policy posted on the DePaul policy page. The new forms reflect the new policy manual and should be used for all new submissions. Older forms will be accepted for the month of September 2016. The new forms are in fillable PDF format. The new manual expands the IBC's purview to activities that might not be covered under the previous policy and expands on IBC coverage of teaching activties. 

Announcement: Updated Hepatitis B Vaccination Acceptance/Declination Statement form (posted: 11/11/14)

When DePaul faculty, staff, or students are working with any materials for research or teaching purposes that may potentially contain the Hepatitis B virus, the IBC will request documentation of proof of vaccination, a signed declination of vaccination, or an indication that the person wants to receive the vaccination through DePaul. The IBC has updated their Hepatitis B form to use the Hepatitis B Vaccination Acceptance/Declination Statement form that is used by Environmental Health and Safety Office. Therefore, there is only one form IBC investigators and their personnel need to complete and submit to both the IBC and Environmental Health and Safety Office. The IBC website also includes instructions for completing the form when the activity is linked to an IBC protocol.

Announcement: Recommendation to consult with the IBC Chair when laboratories utilizing biohazardous agents are renovated or constructed (posted: 11/11/14) 

The IBC recommends that all investigators working with biohazardous agents, regardless of the biosafety containment level 1 or 2 procedures required, consult with the IBC Chair, Dr. Joanna Brooke, when having laboratories renovated or constructed. The IBC Chair will ensure the plans for renovation or lab creation include the proper equipment and standards required to avoid any biosafety concerns and to properly contain the biohazardous agents utilizing the standards as described in the NIH Guidelines and the Biosafety in Microbiological and Biomedical Laboratories (BMBL). 

Individuals who do not currently have active IBC protocols but who may conduct work that requires IBC review and approval in the future are more than welcome to also consult with the IBC Chair regarding their laboratory needs. 

Announcement: Revised NIH Guidelines for Research Involving Recombinant DNA Molecules (posted: 11/12/12)

The National Institutes of Health (NIH) Office of Biotechnology Activities (OBA) has revised the NIH Guidelines for Research Involving Recombinant DNA Molecules to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules to address biosafety considerations for research with synthetic nucleic acids. The changes are effective March 5, 2013. This means that all ongoing and newly proposed experiments that are subject to the revised NIH Guidelines must be submitted by the Principal Investigator (PI) to the DePaul Institutional Biosafety Office (IBC) and approved by March 5, 2013.

The revisions expand the type of research which is subject to the NIH Guidelines to include synthetic nucleic acid molecules, adds hazard classification information for these types of molecules, adds additional responsibilities for the Institutional Biosafety Committee (IBC) when reviewing research involving these molecules, and adds or revises several definitions.

As a reminder, the NIH Guidelines apply to all recombinant DNA research that is conducted or sponsored at or sponsored by institutions that receive NIH funding for any research involving recombinant DNA.

The DePaul IBC will be revising policy to incorporate these changes.

To read the Notice in the Federal Register:

To review FAQs about the changes:​

Announcement: New Guidance document, “Information for Labs Conducting Recombinant DNA Research, Reporting of Incidents Involving Recombinant DNA to the NIH Office of Biotechnology Activities (OBA)” (posted: 11/12/12)

On September 25, 2012 the National Institutes of Health (NIH) Office of Biotechnology Activities (OBA) released a new Frequently Asked Questions guidance document which explains the types of incidents that must be reported to NIH OBA, who is responsible for reporting the incidents, what information must be included in the report, and other useful information about incident reporting.

To read the full FAQ document: ​